Survivin’ Acute Myeloid Leukaemia—A Personalised Target for inv(16) Patients

Despite recent advances in therapies including immunotherapy, patients with acute myeloid leukaemia (AML) still experience relatively poor survival rates. The Inhibition of Apoptosis (IAP) family member, survivin, also known by its gene and protein name, Baculoviral IAP Repeat Containing 5 (BIRC5),...

Descripción completa

Detalles Bibliográficos
Autores principales: Greiner, Jochen, Brown, Elliott, Bullinger, Lars, Hills, Robert K., Morris, Vanessa, Döhner, Hartmut, Mills, Ken I., Guinn, Barbara-ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508831/
https://www.ncbi.nlm.nih.gov/pubmed/34638823
http://dx.doi.org/10.3390/ijms221910482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508831/
https://www.ncbi.nlm.nih.gov/pubmed/34638823
http://dx.doi.org/10.3390/ijms221910482

Ejemplares similares